This book explores the intricate world of epigenetics and its pivotal role in precision medicine and the identification of epigenetic biomarkers for patient stratification, highlighting the importance of non-coding RNAs (ncRNAs), DNA methylation and histone modifications. The book discusses various epigenetic drugs, such as HDAC inhibitors and DNA methyltransferase inhibitors, targeting specific pathways to provide new therapeutic avenues. An important part in each chapter is dedicated to in silico analysis in epigenetics, including genome-wide association studies to identify correlations between genetic variations and epigenetic changes. It also covers computational models that simulate the effects of epigenetic modifications on cellular behaviour, providing insights into clinical trials with prodrugs in various types of cancer. The book focuses on the crucial role of gut microorganisms in hormone metabolism, synthesis of bioactive compounds and maintenance of the immune response, influencing endocrine homeostasis. It explores the interplay between gut microbiota, ncRNAs and endocrine regulation, focusing on endocrine-related cancers. The impact of the gut microbiome on host health through epigenetic changes is examined in depth, with a particular focus on the role of ncRNAs in host-microbe interactions. Advances in liver cell epigenetics are discussed, showing how epigenetic changes contribute to liver disorders and the potential for epigenetic-based therapeutic approaches. The book also addresses the impact of epigenetic modifications in colorectal cancer and breast cancer highlighting their role in inflammation, vascular function and lipid metabolism. Special attention is given to the importance of epigenetics and precision medicine in the context of rare cancers, blood disorders and immune-related diseases. The book reviews current literature, clinical trials and case studies, providing an overview of therapeutic potentials and innovations. It emphasises the importance of patient-centred approaches, collaborative research networks and ethical considerations in advancing the field. This book synthesises findings on the contributions of epigenetics and precision medicine to the treatment of various diseases, advocating interdisciplinary research and continuing education to improve patient care and outcomes.

Autorentext
Professor Nadia M. Hamdy is a renowned researcher with significant contributions to the scientific community since 2003. She has over 111 publications, 5 book chapters, several provisional patency in progress, and a Scopus h-index of 40. Prof. Hamdy has supervised 45 Masters and PhD students and received numerous awards, including the ASU Appreciation award in Technological sciences 2024, ASRT-Egypt State Award Dr. Shawky el Hadad Award in cancer for 2023 and the International BSI Honorary awards and recognition in 2025, Wendy Harvan Top Honorary Award in February 2023 and 2021. Her research interests include pharmaceutical clinical biochemistry, molecular biology, genetic/epigenetics studies, biomarkers, immuno-oncology, biotechnology, and nano-biotechnology. She focuses on understanding genetic and epigenetic mechanisms of cancers and diseases, developing biomarkers for disease prognosis, and exploring innovative therapeutic approaches. Prof. Hamdy is also a member of the editorial board of five Scopus journals and a reviewer for international and regional grants, awards, and scientific journals. Professor Ahmed S. Sultan is a distinguished Professor of Stem Cell and Molecular Oncology at Georgetown University Medical Center. He received his MD/PhD from Osaka University School of Medicine in 1999 and an M.P.H. from Georgetown University in 2005. Dr. Sultan's research interests include clinical biochemistry, molecular biology, gene therapy for breast and liver cancer, and the role of stem cells in cancer models. His innovative research focuses on discovering new methods and treatment strategies for metastatic cancers, isolating and manipulating cancer stem cells versus human cancer cells. Dr. Sultan aims to enhance the quality of life for cancer patients through innovative research. Professor John F. Kennedy is a distinguished scientist with four degrees from The University of Birmingham. He has received prestigious awards such as the Meldola Medal for Chemistry and the Carbohydrate Chemistry Award by the Royal Society of Chemistry. Prof. Kennedy has held various professional appointments, including Director of the Birmingham Carbohydrate and Protein Technology Group and Professor of Applied Chemistry at Glyndwr University. He has published over 800 papers and authored or edited around twenty books. His research interests include carbohydrate chemistry, enzyme technology, and the environmental impact of industrial processes. Prof. Kennedy has been involved in developing innovative solutions for medical and environmental challenges, demonstrating a commitment to advancing science for the benefit of society.

Inhalt

Chapter 1. Epigenetic Modulation of Immunity: Mechanisms, Implications, and Emerging Therapeutic Horizons; a Step-toward Epigenetics-to-Precision.- Chapter 2. The intricate interplay of noncoding RNAs and the gut microbiome in gastrointestinal and endocrine-related cancers.- Chapter 3. Mapping the non-coding epimutation in breast cancer; a Step-toward Epigenetics-to-Precision.- Chapter 4. Unlocking the Epigenetic Landscape of Colorectal Cancer; a Step-toward Epigenetics-to-Precision.- Chapter 5. Non-coding RNAs: A Novel Frontier in Various Liver Cancer Research and Therapy; Implications for Precision Oncology.- Chapter 6. The Epigenetics Angle in Precision Medicine Era for Blood Disorders Advancements.- Chapter 7. A Comprehensive Guide on Epigenetics Precision Role for Uncommon Rare Cancers Biology and Treatment Frontiers.- Chapter 8. An Overview of Targeting Some Cancer Hallmarks with Plant PolyPhenols; a Step-toward Precision.